Demographic data of the study sample
Fatigue | No fatigue | p | |
---|---|---|---|
Data are given as means±SD; p values according to t test or χ2 test*. | |||
CAMBS, Cambridge Multiple Sclerosis Basic Score; EDSS, Expanded Disability Status Scale; ESS, Epworth Sleepiness Scale; FSS, Fatigue Severity Scale; MFIS, modified Fatigue Impact Scale; HADS, Hospital Anxiety and Depression Scale; SDMT, Symbol Digit Modalities Scale. | |||
n | 15 | 15 | |
Age | 46.6±11.69 | 42.87±10.17 | 0.36 |
Gender, M/F | 6/9 | 6/9 | >0.99* |
Years with MS | 13.80±9.68 | 8.60±5.57 | 0.09 |
EDSS | 4.36±1.49 | 2.30±1.84 | 0.002 |
FSS | 6.08±0.68 | 1.51±0.69 | <0.001 |
MFIS | 58.07±10.55 | 7.53±8.08 | <0.001 |
ESS | 10.53±4.71 | 3.27±2.37 | <0.001 |
HADS | 7.93±3.30 | 3.13±3.50 | 0.001 |
CAMBS | |||
Disability | 2.93±0.25 | 1.93±0.79 | <0.001 |
Relapse | 1.33±0.48 | 1.60±0.63 | 0.21 |
Progression | 2.40±0.91 | 1.53±0.63 | 0.01 |
Handicap | 3.60±0.82 | 2.00±1.06 | <0.001 |
SDMT | −0.40±1.72 | 0.13±1.30 | 0.35 |
Disease course | 6 RR, 8 SP, 1 PP | 11 RR, 2 SP, 2 PP | 0.07* |
Treatment | 6 immune modulators,4 immuno-suppressants | 9 immune modulators | 0.51* |